MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 06-06-2026
Biohaven Pharmaceutical Holding Company Ltd. Operating Income 2011-2026 | BHVN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Biohaven Pharmaceutical Holding Company Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -704 M | -645 M | -479 M | -225 M | -108 M | -60.6 M | -9.7 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.7 M | -704 M | -319 M |
Quarterly Operating Income Biohaven Pharmaceutical Holding Company Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -290 M | -53.8 M | - | -140 M | -172 M | -236 M | -171 M | -163 M | -161 M | -151 M | -135 M | -90.5 M | -199 M | -54.5 M | -48.1 M | -54.9 M | -38.1 M | -83.4 M | -28.3 M | -39.6 M | -25.2 M | -14.5 M | -22.8 M | -28 M | -6.85 M | -2.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.98 M | -290 M | -96.3 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-6.78 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-211 M | - | - | $ 2.18 B | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-14.3 M | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
-44.2 M | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-43.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
13.7 B | - | - | $ 96.9 B |  Britain |
 |
CureVac N.V.
CVAC
|
178 M | - | - | $ 867 M | Germany |
 |
Athira Pharma
ATHA
|
-102 M | - | - | $ 269 M | USA |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.38 | -2.82 % | $ 162 M | USA |
 |
Abcam plc
ABCM
|
-10.1 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
-2.54 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-8.64 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-107 M | - | -34.95 % | $ 21.5 M | Germany |
 |
CRISPR Therapeutics AG
CRSP
|
-665 M | $ 49.99 | -2.89 % | $ 4.5 B |  Schweiz |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 29.54 | -0.2 % | $ 1.96 B | USA |
 |
Generation Bio Co.
GBIO
|
-142 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
|
Enlivex Therapeutics Ltd.
ENLV
|
-15 M | $ 0.7 | 1.33 % | $ 32 M | Israel |
 |
Esperion Therapeutics
ESPR
|
60.3 M | $ 3.15 | 0.32 % | $ 655 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-844 K | $ 31.07 | 1.77 % | $ 836 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-8.43 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-98.4 M | - | - | $ 384 M | Britain |
 |
Exelixis
EXEL
|
872 M | $ 53.14 | 0.27 % | $ 14.4 B | USA |
 |
Gracell Biotechnologies
GRCL
|
-625 M | - | - | $ 3.37 B | China |
|
Forte Biosciences
FBRX
|
-70.7 M | $ 16.84 | -0.94 % | $ 218 M | USA |
 |
Anika Therapeutics
ANIK
|
-11.1 M | $ 14.71 | 0.96 % | $ 211 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.7 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 2.94 | 1.03 % | $ 4.84 M | Israel |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |